Zobrazeno 1 - 10
of 20
pro vyhledávání: '"H L Janssen"'
Publikováno v:
Journal of the Canadian Association of Gastroenterology. 4:243-244
Background Sexual transmission of hepatitis C virus (HCV) is well-documented among HIV-uninfected individuals. The use of HIV pre-exposure prophylaxis (PrEP) may lead to increased engagement in activities that facilitate the transmission of sexually
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e265cd6e996dc65fe4f6140eb608ff9c
https://doi.org/10.1093/jcag/gwab002.210
https://doi.org/10.1093/jcag/gwab002.210
Autor:
H L, Janssen
Publikováno v:
Scandinavian journal of gastroenterology. Supplement. (232)
The aetiology of portal vein thrombosis (PVT) is heterogeneous. Important primary risk factors for PVT are cirrhosis, hepatobiliary malignancies and pancreatitis. Newly discovered thrombotic risk factors, such as latent myeloproliferative disorders a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e775f545d1a43fca38a005cb535f6dd0
https://pubmed.ncbi.nlm.nih.gov/11232496
https://pubmed.ncbi.nlm.nih.gov/11232496
Publikováno v:
Journal of medical virology. 63(3)
Chronic hepatitis B patients with low pre-treatment HBeAg (and HBV-DNA) levels are more likely to respond to interferon-alpha therapy. In retrospect, this low level of HBeAg may have been reached just before the start of therapy. Pre-treatment change
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2c3d33776e6e781614b7466d703aa514
https://pubmed.ncbi.nlm.nih.gov/11170060
https://pubmed.ncbi.nlm.nih.gov/11170060
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 143(41)
Portal vein thrombosis (PVT) has a heterogeneous aetiology. Recently discovered thrombotic risk factors such as latent myeloproliferative disorders and prothrombotic genetic defects are important in the aetiology of PVT. At least one-third of the PVT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ce52133143a7fe1bc81a365ed42ac4ed
https://pubmed.ncbi.nlm.nih.gov/10560543
https://pubmed.ncbi.nlm.nih.gov/10560543
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 143(37)
The possibilities for antiviral treatment of patients with chronic hepatitis B virus (HBV) infections have been in flux for the last few years. Apart from interferon alpha, oral nucleoside analogues are given a place. The treatment focuses on the gro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::179f9f2685faf2f34223ee4039679eb0
https://pubmed.ncbi.nlm.nih.gov/10526598
https://pubmed.ncbi.nlm.nih.gov/10526598
Autor:
H L, Janssen, J M, van Laar, B, van Hoek, G J, den Ottolander, J H, van Krieken, F C, Breedveld
Publikováno v:
Digestive diseases and sciences. 44(8)
Adult-onset Still's disease is a systemic inflammatory disorder with a highly variable clinical course. Mild hepatitis and anemia are common manifestations. We describe a patient with adult Still's disease who developed a severe hepatitis and a life-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9f42eacd476d1c42395d99ad257112dc
https://pubmed.ncbi.nlm.nih.gov/10492146
https://pubmed.ncbi.nlm.nih.gov/10492146
Publikováno v:
SPIE Proceedings.
In the framework of the Dutch government humanitarian demining project 'HOM-2000', an outdoor test facility has been realized to test, improve and develop detection equipment for land mines. This sophisticated facility, allows us to access and compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be4b8e50cf7e3c9f2b6a5acbb2991188
https://doi.org/10.1117/12.357030
https://doi.org/10.1117/12.357030
Autor:
H L, Janssen, G, Gerken, V, Carreño, P, Marcellin, N V, Naoumov, A, Craxi, H, Ring-Larsen, G, Kitis, J, van Hattum, R A, de Vries, P P, Michielsen, F J, ten Kate, W C, Hop, R A, Heijtink, P, Honkoop, S W, Schalm
Publikováno v:
Hepatology (Baltimore, Md.). 30(1)
Interferon alfa (IFN-alpha) is the primary treatment for chronic hepatitis B. The standard duration of IFN-alpha therapy is considered 16 weeks; however, the optimal treatment length is still poorly defined. We evaluated the efficacy and acceptabilit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e55e1884379e5c0cfe61bbe404d76883
https://pubmed.ncbi.nlm.nih.gov/10385662
https://pubmed.ncbi.nlm.nih.gov/10385662
Publikováno v:
SPIE Proceedings.
We analyzed a time series of high resolution 8 - 13.4 μm scanner images of a sandbox with buried (3 - 10 cm depth) and unburied, metal and plastic AP and AT mines, surrogates and other targets. With a high resolution DUDA scanner operating in 8 - 13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4832ae3bc40d7d9dfc9b794706fe38ea
https://doi.org/10.1117/12.241248
https://doi.org/10.1117/12.241248